Literature DB >> 30575898

Involvement of circular RNA SMARCA5/microRNA-620 axis in the regulation of cervical cancer cell proliferation, invasion and migration.

J-J Dai C Tian1, L Liang.   

Abstract

OBJECTIVE: Circular RNAs (circRNAs) have emerged as crucial regulators for tumor progression. However, the effects of circRNAs are not entirely clear in cervical cancer (CC). The objective of this study was to investigate the function and regulation mechanism of circular RNA SMARCA5 (circSMARCA5, also named hsa_circ_0001445) in cervical cancer. PATIENTS AND METHODS: circSMARCA5 and miR-620 expressions were analyzed by qRT-PCR assay. The cell proliferation, cell cycle, migration, invasion abilities were measured by CCK-8 and colony formation, Flow cytometry, Wound-healing and transwell assays. In addition, the interaction between circSMARCA5 and miR-620 was accessed by luciferase reporter assay.
RESULTS: The results indicated that circSMARCA5 was downregulated in CC; overexpression of circSMARCA5 inhibited CC cell proliferation, migration and invasion, and induced cell cycle arrest. In addition, we found that circSMARCA5 could bind to miR-620 and significantly downregulated its expression. Furthermore, the results revealed that circSMARCA5 suppressed proliferation and invasion by miR-620 in CC.
CONCLUSIONS: We suggested that circSMARCA5/miR-620 regulatory axis is involved in the development of CC and may serve as a potential therapy target.

Entities:  

Year:  2018        PMID: 30575898     DOI: 10.26355/eurrev_201812_16622

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  31 in total

1.  Circular RNA SMARCA5 functions as an anti-tumor candidate in colon cancer by sponging microRNA-552.

Authors:  Shiwei Yang; Shanyu Gao; Tongming Liu; Junning Liu; Xia Zheng; Zhi Li
Journal:  Cell Cycle       Date:  2021-03-22       Impact factor: 4.534

2.  Apatinib inhibits cell proliferation and migration of osteosarcoma via activating LINC00261/miR-620/PTEN axis.

Authors:  Gang Han; Quanyi Guo; Ning Ma; Wenzhi Bi; Meng Xu; Jinpeng Jia
Journal:  Cell Cycle       Date:  2021-08-23       Impact factor: 5.173

3.  lncRNA PICART1 alleviates progression of cervical cancer by upregulating TCF21.

Authors:  Yunxia Zhao; Xiuxian Dong; Rong Hou
Journal:  Oncol Lett       Date:  2020-03-27       Impact factor: 2.967

4.  MiR-146b-5p suppresses the malignancy of GSC/MSC fusion cells by targeting SMARCA5.

Authors:  Haiyang Wang; Liping Tan; Xuchen Dong; Liang Liu; Qianqian Jiang; Haoran Li; Jia Shi; Xuejun Yang; Xingliang Dai; Zhiyuan Qian; Jun Dong
Journal:  Aging (Albany NY)       Date:  2020-07-06       Impact factor: 5.682

5.  Involvement of a novel circularRNA, hsa_circ_0000520, attenuates tumorigenesis of cervical cancer cell through competitively binding with miR-146b-3p.

Authors:  Jinling Zhang; Ruyu Cai; Yifan Zhang; Xiaoyu Wang
Journal:  J Cell Mol Med       Date:  2020-06-27       Impact factor: 5.310

6.  Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p.

Authors:  Haiyan Liu; Yan Wu; Shunye Wang; Jie Jiang; Chenlu Zhang; Yijing Jiang; Xingfeng Wang; Lewen Hong; Hongming Huang
Journal:  BMC Cancer       Date:  2019-10-10       Impact factor: 4.430

7.  Circular RNA SMARCA5 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by miR-19b-3p/HOXA9 axis.

Authors:  Yaqiu Wang; Huiping Li; Hong Lu; Yaguang Qin
Journal:  Onco Targets Ther       Date:  2019-08-30       Impact factor: 4.147

8.  Circ_0001666 affects miR-620/WNK2 axis to inhibit breast cancer progression.

Authors:  Na Su; Li Liu; Shan He; Linghai Zeng
Journal:  Genes Genomics       Date:  2021-06-01       Impact factor: 1.839

9.  hsa_circ_0008285 Facilitates the Progression of Cervical Cancer by Targeting miR-211-5p/SOX4 Axis.

Authors:  Youpeng Bai; Xicong Li
Journal:  Cancer Manag Res       Date:  2020-05-26       Impact factor: 3.989

10.  Response to: Comment on "circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer".

Authors:  Juan Cai; Zhiqiang Chen; Xueliang Zuo
Journal:  Dis Markers       Date:  2019-09-23       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.